S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
NASDAQ:ACHV

Achieve Life Sciences - ACHV Stock Forecast, Price & News

$4.98
+0.02 (+0.40%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.95
$5.05
50-Day Range
$4.88
$6.90
52-Week Range
$4.81
$10.09
Volume
46,518 shs
Average Volume
21,013 shs
Market Capitalization
$48.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
408.3% Upside
$25.33 Price Target
Short Interest
Healthy
3.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.03) to ($1.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

935th out of 1,293 stocks

Diagnostic Substances Industry

13th out of 26 stocks

ACHV stock logo

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer increased their target price on shares of Achieve Life Sciences from $23.00 to $27.00 in a research note on Wednesday, April 27th.

Achieve Life Sciences Price Performance

ACHV Stock traded up $0.07 during mid-day trading on Monday, hitting $5.03. 11 shares of the company were exchanged, compared to its average volume of 56,473. The company has a current ratio of 9.40, a quick ratio of 9.40 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $5.56 and a 200-day simple moving average of $6.65. Achieve Life Sciences has a 12-month low of $4.81 and a 12-month high of $10.09.

Achieve Life Sciences (NASDAQ:ACHV - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.02. During the same quarter in the previous year, the business posted ($1.30) earnings per share. As a group, equities research analysts predict that Achieve Life Sciences will post -3.03 earnings per share for the current year.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

Achieve Life Sciences Inc - Stock Quote ACHV
Achieve Life Sciences Inc - Stock News
ACHV: First Quarter 2022 Results
Achieve Life Sciences Tops Q1 EPS by 1c
ACHV: Topline Data from ORCA-2 Smoking Cessation Trial
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings
5/12/2022
Today
8/08/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.33
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+408.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.97 per share

Miscellaneous

Free Float
9,585,000
Market Cap
$48.25 million
Optionable
Not Optionable
Beta
1.20

Key Executives

  • Dr. Richard A. B. Stewart (Age 63)
    Exec. Chairman
    Comp: $660k
  • Mr. John A. Bencich M.B.A. (Age 45)
    CEO & Director
    Comp: $767.25k
  • Dr. Cindy Jacobs M.D. (Age 64)
    Ph.D., Pres, Chief Medical Officer & Director
    Comp: $668.8k
  • Mr. Jerry Wan (Age 40)
    Principal Accounting Officer
  • Dr. Anthony Clarke (Age 66)
    Chief Scientific Officer
  • Ms. Jaime Xinos
    Exec. VP of Commercial













ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price forecast for 2022?

2 Wall Street analysts have issued twelve-month price targets for Achieve Life Sciences' shares. Their ACHV share price forecasts range from $24.00 to $27.00. On average, they anticipate the company's share price to reach $25.33 in the next year. This suggests a possible upside of 408.3% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How has Achieve Life Sciences' stock performed in 2022?

Achieve Life Sciences' stock was trading at $7.78 on January 1st, 2022. Since then, ACHV shares have decreased by 35.9% and is now trading at $4.9840.
View the best growth stocks for 2022 here
.

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our ACHV earnings forecast
.

How can I listen to Achieve Life Sciences' earnings call?

Achieve Life Sciences will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.02. During the same quarter in the prior year, the firm posted ($1.30) EPS.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences's stock reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (2.36%) and Granite Point Capital Management L.P. (0.14%).
View institutional ownership trends
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $4.98.

How much money does Achieve Life Sciences make?

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $48.26 million. The biopharmaceutical company earns $-33,150,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Achieve Life Sciences have?

Achieve Life Sciences employs 16 workers across the globe.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.